section name header

Pronunciation

zoe-led-DRON-ic AS-id

Classifications

Therapeutic Classification: bone resorption inhibitors, electrolyte modifiers, hypocalcemics

Pharmacologic Classification:

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Concentrated in and binds to bone.

Metabolism/Excretion: Mostly excreted unchanged by the kidneys.

Half-life: 167 hr.

Time/Action Profile

(effect on serum calcium)

ROUTEONSETPEAKDURATION
IVwithin 4 days4–7 days30 days

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, chest pain, leg edema.

Derm: pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

EENT: conjunctivitis.

F and E: hypophosphatemia, hypocalcemia, hypokalemia, hypomagnesemia.

GI: abdominal pain, constipation, diarrhea, nausea, vomiting, dysphagia.

GU: fertility (females), renal impairment/failure.

Hemat: anemia.

MS: musculoskeletal pain, femur fractures, osteonecrosis (primarily ONJ).

Neuro: agitation, anxiety, confusion, insomnia.

Resp: asthma exacerbation.
Misc: fever, flu-like syndrome.

Interactions

Drug-Drug:

Route/Dosage

Paget's Disease

Treatment of Osteoporosis in Men or Postmenopausal Women or Treatment/Prevention of Glucocorticoid-Induced Osteoporosis

Prevention of Osteoporosis in Postmenopausal Women

Hypercalcemia of Malignancy

Multiple Myeloma or Bone Metastases from Solid Tumors

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Reclast

Canadian Brand Names

Aclasta, Zometa